-

11:52:46 AM

ACHFF Stock News

ACHFF - Arch Biopartners, Inc.

01/04/22 7:25 AM

OTC : ACHFF

covid-19

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

Arch Biopartners Inc. (“Arch

RHEA-AI

neutral

12/01/21 7:35 AM

OTC : ACHFF

covid-19

Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant type. LSALT is the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a

RHEA-AI

neutral

08/05/21 6:30 AM

OTC : ACHFF

Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of

RHEA-AI

neutral

07/14/21 7:00 AM

OTC : ACHFF

Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Arch scientists have been awarded a

RHEA-AI

very positive

06/10/21 7:20 AM

OTC : ACHFF

Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent

RHEA-AI

neutral

05/04/21 7:00 AM

OTC : ACHFF

covid-19

Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has completed enrollment for its Phase II

RHEA-AI

neutral

04/15/21 7:00 AM

OTC : ACHFF

Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury

Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation Novel Mechanism of Action - selective dipeptidase-1 (DPEP-1) antagonists that prevent leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ

RHEA-AI

neutral

03/30/21 7:57 AM

OTC : ACHFF

Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry of Health, Pharmaceuticals and Medical Devices Agency (MoH) to recruit up to twenty additional

RHEA-AI

neutral

03/16/21 8:32 AM

OTC : ACHFF

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for preventing organ inflammation, announced today that Health Canada has provided a No Objection Letter for

RHEA-AI

neutral

03/04/21 8:32 AM

OTC : ACHFF

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett, Professor at the University of Cincinnati College of Medicine, published a paper entitled “AB569,

RHEA-AI

neutral

ACHFF Data:

IndustryMiscellaneous Commercial Services
Websitehttp://www.archbiopartners.com
CeoRichard Gabriel Muruve
Security nameArch Biopartners, Inc.
Issue typecs
SectorCommercial Services
Sic code8731
Tags
- Advertising/Marketing Services
- Commercial Services
- Miscellaneous Commercial Services
Address545 King Street West
StateON
CityToronto
ZipM5V
CountryCA
Phone1.647.428.7031

ACHFF Description:

Arch Biopartners, Inc. is a portfolio based biotechnology company. It is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. The company has five technology platforms which includes: AB569, MetaBlok, Arch Inflammation, Borg:Peptide-Solid Surface Interface and MetaMx. Arch Biopartners was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.